2011
DOI: 10.1007/s10151-011-0732-2
|View full text |Cite
|
Sign up to set email alerts
|

Management of concurrent colorectal cancer and vascular disease in the endovascular era

Abstract: Priority of treating concurrent vascular disease and CRC remains a dilemma. Combined treatment with a single-stage procedure is feasible. Risk of graft infection may be lower than expected.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 10 publications
0
2
0
Order By: Relevance
“…Whereas, for the fear of precipitating aneurysmal rupture, medical oncologists were very reluctant to perform neoadjuvant chemoradiation with an unrepaired AAA [23, 24]. Therefore, endovascular repair of AAA or AAD first may allow safe performance of neoadjuvant chemoradiation therapy for downstaging of gastrointestinal cancer [2, 23]. After 115 days of endovascular repair, one patient (case 1) with rectal cancer was treated from open surgery with neoadjuvant chemotherapy (FOLFOX regimen, 3 courses).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Whereas, for the fear of precipitating aneurysmal rupture, medical oncologists were very reluctant to perform neoadjuvant chemoradiation with an unrepaired AAA [23, 24]. Therefore, endovascular repair of AAA or AAD first may allow safe performance of neoadjuvant chemoradiation therapy for downstaging of gastrointestinal cancer [2, 23]. After 115 days of endovascular repair, one patient (case 1) with rectal cancer was treated from open surgery with neoadjuvant chemotherapy (FOLFOX regimen, 3 courses).…”
Section: Discussionmentioning
confidence: 99%
“…As the aging population increases, the incidence of gastrointestinal cancer and vascular diseases, such as abdominal aortic aneurysm (AAA) and abdominal aortic dissection (AAD), has increased [1, 2]. Though the true incidence is difficult to accurately ascertain, the synchronous presentation of AAA or AAD and gastrointestinal tumor is still rare (0.49% to 2.1% in most series [3, 4]).…”
Section: Introductionmentioning
confidence: 99%